首页> 外文期刊>Biomaterials >Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
【24h】

Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.

机译:聚(丙交酯)-D-α-生育酚聚乙二醇琥珀酸酯二嵌段共聚物与转铁蛋白结合的纳米颗粒,用于跨血脑屏障的靶向药物递送。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We developed in this research a nanoparticle system for targeted drug delivery across the blood-brain barrier (BBB), which consists of the transferrin (Tf) conjugated nanoparticles of poly(lactide)-D-alpha-Tocopheryl polyethylene glycol succinate (PLA-TPGS) diblock copolymer. The NPs were prepared by the nanoprecipitation method and characterized for their various physicochemical and pharmaceutical properties. Cellular uptake and cytotoxicity of the Tf-conjugated PLA-TPGS NPs formulation of coumarin 6 as a model imaging agent or Docetaxel as a model drug were investigated in close comparison with those for the PLGA NPs formulation, the bare PLA-TPGS NPs formulation as well as with the clinical Taxotere. The Tf-conjugated PLA-TPGS NPs formulation demonstrated great advantages over the other two NPs formulations and the original imaging/therapeutic agents. IC50 data showed that the Tf-conjugated PLA-TPGS NPs formulation of Docetaxel could be 23.4%, 16.9% and 229% more efficient than the PLGA NPs, the PLA-TPGS NPs formulations and Taxotere after 24 h treatment, respectively. Moreover, our preliminary ex vivo biodistribution investigation demonstrated that although not as satisfactory, the Tf-conjugated PLA-TPGS NPs formulation could be able to deliver imaging/therapeutic agents across the BBB.
机译:我们在这项研究中开发了一种跨血脑屏障(BBB)进行靶向药物递送的纳米颗粒系统,该系统由聚乳酸-D-α-生育酚聚乙二醇琥珀酸酯(PLA-TPGS)的转铁蛋白(Tf)共轭纳米颗粒组成)二嵌段共聚物。通过纳米沉淀法制备NP,并对其各种理化和药物特性进行表征。与PLGA NPs制剂,裸露的PLA-TPGS NPs制剂相比,香豆素6作为模型成像剂或Docetaxel作为模型药物的Tf共轭PLA-TPGS NPs制剂的细胞摄取和细胞毒性进行了研究。就像临床的Taxotere一样。与其他两种NPs制剂和原始成像/治疗剂相比,与Tf偶联的PLA-TPGS NPs制剂表现出极大的优势。 IC50数据显示,多西他赛的Tf共轭PLA-TPGS NPs制剂在处理24小时后的效率分别比PLGA NPs,PLA-TPGS NPs和Taxotere高23.4%,16.9%和229%。此外,我们的初步离体生物分布研究表明,尽管不尽如人意,但Tf偶联的PLA-TPGS NPs制剂仍能够在整个BBB上递送成像/治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号